Association of funding and findings of pharmaceutical research at a meeting of a medical professional society

被引:57
作者
Finucane, TE
Boult, CE
机构
[1] Johns Hopkins Univ, Sch Med, Div Geriatr Med & Gerontol, Dept Med, Baltimore, MD 21224 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Div Hlth Serv Res, Dept Hlth Policy & Management, Baltimore, MD USA
关键词
D O I
10.1016/j.amjmed.2004.05.029
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE: To evaluate the association between funding and findings of pharmaceutical research presented at an annual meeting of a medical professional society. METHODS: We reviewed the abstracts of all papers and posters presented at the annual meeting of a medical professional society. Two independent raters classified each study of a drug (n = 48) as either positive (favoring the drug studied) or negative, and as either funded by a pharmaceutical company or not. We computed K and chi-squared statistics to evaluate the agreement between the raters, as well as the association between the results and the sponsorship of the study. RESULTS: Thirty studies of drugs (63%) were supported by pharmaceutical companies, all of which reported positive results. Of the 18 studies (37%) not supported by pharmaceutical companies, 67% reported positive results. The association between pharmaceutical funding and positive findings was statistically significant (P = 0.0007). CONCLUSION: At this scientific meeting, research funding from pharmaceutical companies was associated with study findings that supported the use of drugs marketed by pharmaceutical sponsors. We emphasize further study of this relation and suggest three principles-full disclosure, policies against "Outcome bias," and educational opportunities-that may help manage industry-academia conflicts of interest that could otherwise jeopardize the credibility of pharmaceutical research presented at scientific rriectings. (C) 2004 by Elsevier Inc.
引用
收藏
页码:842 / 845
页数:4
相关论文
共 26 条
[1]   Conflicts of interest - Science, money, and health [J].
Alpert, JS .
ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (06) :635-637
[2]   Is academic medicine for sale? [J].
Angell, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (20) :1516-1518
[3]  
*ASS AM MED COLL T, PROT SUBJ PRES TRUST, V2
[4]   Scope and impact of financial conflicts of interest in biomedical research - A systematic review [J].
Bekelman, JE ;
Li, Y ;
Gross, CP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (04) :454-465
[5]   Uneasy alliance - Clinical investigators and the pharmaceutical industry [J].
Bodenheimer, T .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (20) :1539-1544
[6]   Positive-outcome bias and other limitations in the outcome of research abstracts submitted to a scientific meeting [J].
Callaham, ML ;
Wears, RL ;
Weber, EJ ;
Barton, C ;
Young, G .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (03) :254-257
[7]   Physician-industry relations. Part 1: Individual physicians [J].
Coyle, SL .
ANNALS OF INTERNAL MEDICINE, 2002, 136 (05) :396-402
[8]   Physician-industry relations. Part 2: Organizational issues [J].
Coyle, SL .
ANNALS OF INTERNAL MEDICINE, 2002, 136 (05) :403-406
[9]   Reporting financial conflicts of interest and relationships between investigators and research sponsors [J].
DeAngelis, CD ;
Fontanarosa, PB ;
Flanagin, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01) :89-91
[10]   Evaluation of conflict of interest in economic analyses of new drugs used in oncology [J].
Friedberg, M ;
Saffran, B ;
Stinson, TJ ;
Nelson, W ;
Bennett, CL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (15) :1453-1457